Emmaus Life Sciences Provides Interim Shipment Data
TORRANCE, Calif., April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31, 2023.
- TORRANCE, Calif., April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31, 2023.
- "We look forward to reporting our complete interim financial results on our Forms 10-Q for the first quarter as soon as possible.
- In the meantime, we are pleased to provide information regarding our interim volume of shipments," said Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer.
- The shipment volume trend has been as follows: